Literature DB >> 30300753

High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain.

Xiaotian T Fang1, Greta Hultqvist2, Silvio R Meier3, Gunnar Antoni4, Dag Sehlin3, Stina Syvänen3.   

Abstract

PET imaging of amyloid-beta (Aβ) deposits in brain has become an important aid in Alzheimer's disease diagnosis, and an inclusion criterion for patient enrolment into clinical trials of new anti-Aβ treatments. Available PET radioligands visualizing Aβ bind to insoluble fibrils, i.e. Aβ plaques. Levels of prefibrillar Aβ forms, e.g. soluble oligomers and protofibrils, correlate better than plaques with disease severity and these soluble species are the neurotoxic form of Aβ leading to neurodegeneration. The goal was to create an antibody-based radioligand, recognizing not only fibrillary Aβ, but also smaller and still soluble aggregates. We designed and expressed a small recombinant bispecific antibody construct, di-scFv 3D6-8D3, targeting the Aβ N-terminus and the transferrin receptor (TfR). Natively expressed at the blood-brain barrier (BBB), TfR could thus be used as a brain-blood shuttle. Di-scFv 3D6-8D3 bound to Aβ1-40 with high affinity and to TfR with moderate affinity. Di-scFv [124I]3D6-8D3 was injected in two transgenic mouse models overexpressing human Aβ and wild-type control mice and PET scanned at 14, 24 or 72 h after injection. Di-scFv [124I]3D6-8D3 was retained in brain of transgenic animals while it was cleared from wild-type lacking Aβ. This difference was observed from 24 h onwards, and at 72 h, 18 months old transgenic animals, with high load of Aβ pathology, displayed SUVR of 2.2-3.5 in brain while wild-type showed ratios close to unity. A subset of the mice were also scanned with [11C]PIB. Again wt mice displayed ratios of unity while transgenes showed slightly, non-significantly, elevated SUVR of 1.2, indicating improved sensitivity with novel di-scFv [124I]3D6-8D3 compared with [11C]PIB. Brain concentrations of di-scFv [124I]3D6-8D3 correlated with soluble Aβ (p < 0.0001) but not with total Aβ, i.e. plaque load (p = 0.34). We have successfully created a small bispecific antibody-based radioligand capable of crossing the BBB, subsequently binding to and visualizing intrabrain Aβ in vivo. The radioligand displayed better sensitivity compared with [11C]PIB, and brain concentrations correlated with soluble neurotoxic Aβ aggregates.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid beta; Antibody-based radioligand; Brain; PET; Transferrin receptor

Mesh:

Substances:

Year:  2018        PMID: 30300753     DOI: 10.1016/j.neuroimage.2018.10.011

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  14 in total

1.  Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.

Authors:  Vijay Gupta; Safa Salim; Issam Hmila; Nishant N Vaikath; Indulekha P Sudhakaran; Simona S Ghanem; Nour K Majbour; Sara A Abdulla; Mohamed M Emara; Houari B Abdesselem; Tamas Lukacsovich; Daniel Erskine; Omar M A El-Agnaf
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

Review 2.  Congo Red and amyloids: history and relationship.

Authors:  Elmira I Yakupova; Liya G Bobyleva; Ivan M Vikhlyantsev; Alexander G Bobylev
Journal:  Biosci Rep       Date:  2019-01-15       Impact factor: 3.840

Review 3.  Engineered antibodies: new possibilities for brain PET?

Authors:  Dag Sehlin; Stina Syvänen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-24       Impact factor: 9.236

4.  Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody.

Authors:  Takahiro Morito; Ryuichi Harada; Ren Iwata; Yiqing Du; Nobuyuki Okamura; Yukitsuka Kudo; Kazuhiko Yanai
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

5.  Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain.

Authors:  Fadi Rofo; Canan Ugur Yilmaz; Nicole Metzendorf; Tobias Gustavsson; Chiara Beretta; Anna Erlandsson; Dag Sehlin; Stina Syvänen; Per Nilsson; Greta Hultqvist
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

6.  Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-β in Brain.

Authors:  Stina Syvänen; Xiaotian T Fang; Rebecca Faresjö; Johanna Rokka; Lars Lannfelt; Dag E Olberg; Jonas Eriksson; Dag Sehlin
Journal:  ACS Chem Neurosci       Date:  2020-11-25       Impact factor: 4.418

Review 7.  The Amyloid-β Pathway in Alzheimer's Disease.

Authors:  Harald Hampel; John Hardy; Kaj Blennow; Christopher Chen; George Perry; Seung Hyun Kim; Victor L Villemagne; Paul Aisen; Michele Vendruscolo; Takeshi Iwatsubo; Colin L Masters; Min Cho; Lars Lannfelt; Jeffrey L Cummings; Andrea Vergallo
Journal:  Mol Psychiatry       Date:  2021-08-30       Impact factor: 15.992

8.  Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size.

Authors:  Rebecca Faresjö; Gillian Bonvicini; Xiaotian T Fang; Ximena Aguilar; Dag Sehlin; Stina Syvänen
Journal:  Fluids Barriers CNS       Date:  2021-06-02

9.  Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer's Disease.

Authors:  Silvio R Meier; Dag Sehlin; Greta Hultqvist; Stina Syvänen
Journal:  Mol Imaging Biol       Date:  2021-02-23       Impact factor: 3.488

10.  11C-PiB and 124I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention.

Authors:  Silvio R Meier; Dag Sehlin; Sahar Roshanbin; Victoria Lim Falk; Takashi Saito; Takaomi C Saido; Ulf Neumann; Johanna Rokka; Jonas Eriksson; Stina Syvänen
Journal:  J Nucl Med       Date:  2021-06-04       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.